Single low-dose nanovaccine for long-term protection against anthrax toxins

Summary

This preclinical study develops a single-dose biomimetic vaccine against anthrax toxins, seeking a simpler alternative to prolonged antibody treatment, antibiotics, or multi-step prophylactic vaccination. The formulation uses nanoparticles coated with macrophage membrane. Anthrax toxins are bound to that membrane through the natural interaction between macrophages and protective antigen, a central toxin component. Presenting the captured toxin in this membrane-associated form creates a nanotoxoid intended to preserve immune recognition while preventing toxic activity. An adjuvant was included to strengthen the response. In mice, one low-dose immunization generated immunity that persisted and protected animals from a later anthrax-toxin challenge. The principal finding is that natural toxin–host binding can be repurposed to construct a safe antigen presentation system requiring only a small, single vaccination in the reported model. This supports biomimetic nanotoxoids as a possible preparedness tool for livestock outbreaks or deliberate exposure. The abstract does not state the duration or magnitude of protection, toxin components and challenge details, antibody and cellular correlates, safety measurements, comparison with licensed vaccination strategies, or protection against live Bacillus anthracis infection.